CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 93 enrolled
Drug / intervention
GVAX Pancreas +2 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01417000
NCT01417000Phase 2Completed
CompareCT.gov

A Phase 2, Randomized, Multicenter, Open-Label Study of the Efficacy and Immune Response of the Sequential Administration of GVAX Pancreas Vaccine Alone or Followed by CRS-207 in Adults With Metastatic Pancreatic Adenocarcinoma

Aduro Biotech, Inc.·interventional·Posted Aug 16, 2011·Updated May 8, 2018

In Brief

A Phase 2 clinical trial evaluating GVAX Pancreas, CRS-207, and 1 other intervention for Metastatic Pancreatic Cancer. Completed, enrolled 93 participants across 10 sites.

Detailed Summary

Test the safety, immune response and efficacy of GVAX pancreas vaccine (with cyclophosphamide) and CRS-207 compared to GVAX pancreas vaccine (with cyclophosphamide) alone in adults who have failed or refused prior treatment for metastatic pancreatic cancer.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMetastatic Pancreatic Cancer
CountriesUnited States
CollaboratorsJohns Hopkins University

Timeline

Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedAug 16, 2011
Enrollment StartSep 21, 2011
Primary CompletionOct 1, 2016
Study CompletionFeb 10, 2017
TodayJul 2, 2026
Enrollment to primary: 5.0 yearsPosted 14.9 years ago

Interventions

GVAX Pancreasbiological

CRS-207biological

Cyclophosphamidedrug